Sesen Bio (SESN) Vicineum might reach $1B in annual US peak sales by 2025 - Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity’s analyst John Newman believes that Vicineum, currently in the Phase 3 VISTA trial, could eventually generate $1 billion ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
